Valion Bio, Inc. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2026-08-14: Disclosure Rule10b51Arr Terminated; Period 2026-01-01..2026-06-30; Value No.
- 2026-08-14: Disclosure Non Rule10b51Arr Terminated; Period 2026-01-01..2026-06-30; Value No.
- 2026-08-14: Disclosure Rule10b51Arr Adopted; Period 2026-01-01..2026-06-30; Value No.
- 2026-08-14: Disclosure Non Rule10b51Arr Adopted; Period 2026-01-01..2026-06-30; Value No.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2026-08-14 10-Q | Rule10b51Arr Terminated | 2026-01-01..2026-06-30 | No | |
| 2026-08-14 10-Q | Non Rule10b51Arr Terminated | 2026-01-01..2026-06-30 | No | |
| 2026-08-14 10-Q | Rule10b51Arr Adopted | 2026-01-01..2026-06-30 | No | |
| 2026-08-14 10-Q | Non Rule10b51Arr Adopted | 2026-01-01..2026-06-30 | No | |
| 2026-08-14 10-Q | Material Terms Of Trading Arrangement | 2026-01-01..2026-06-30 | Item 5. Other Information Rule 10b5 - 1 Trading Plans During the three months ended June 30, 2026 , none of our directors or officers informed us of any adoption, modification or termination of a “Rule 10b5 - 1 trading arrangement” or “non-Rule 10b5 - 1 trading arrangement,” that were intended to sa… | |
| 2026-05-14 10-Q | Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-05-14 10-Q | Non Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-05-14 10-Q | Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-14 10-Q | Non Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-14 10-Q | Material Terms Of Trading Arrangement | 2026-01-01..2026-03-31 | Item 5. Other Information Rule 10b5 - 1 Trading Plans During the three months ended March 31, 2026 , none of our directors or officers informed us of any adoption, modification or termination of a “Rule 10b5 - 1 trading arrangement” or “non-Rule 10b5 - 1 trading arrangement,” that were intended to s… | |
| 2026-03-30 10-K | Rule10b51Arr Terminated | 2025-01-01..2025-12-31 | No | |
| 2026-03-30 10-K | Non Rule10b51Arr Terminated | 2025-01-01..2025-12-31 | No | |
| 2026-03-30 10-K | Rule10b51Arr Adopted | 2025-01-01..2025-12-31 | No | |
| 2026-03-30 10-K | Non Rule10b51Arr Adopted | 2025-01-01..2025-12-31 | No | |
| 2026-03-30 10-K | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2026-03-30 10-K | Award Timing MNPI Considered | 2025-01-01..2025-12-31 | No | |
| 2026-03-30 10-K | Material Terms Of Trading Arrangement | 2025-01-01..2025-12-31 | Item 9B - Other Information Securities Trading Plans of Directors and Executive Officers During the three months ended December 31, 2025 , none of our directors or officers entered into, modified or terminated a “Rule 10b5 - 1 trading arrangement” or “non-Rule 10b5 - 1 trading arrangement,” that wer… | |
| 2025-11-14 10-Q | Rule10b51Arr Terminated | 2025-01-01..2025-09-30 | No | |
| 2025-11-14 10-Q | Rule10b51Arr Adopted | 2025-01-01..2025-09-30 | No | |
| 2025-11-14 10-Q | Non Rule10b51Arr Terminated | 2025-01-01..2025-09-30 | No | |
| 2025-11-14 10-Q | Non Rule10b51Arr Adopted | 2025-01-01..2025-09-30 | No | |
| 2025-11-14 10-Q | Material Terms Of Trading Arrangement | 2025-01-01..2025-09-30 | Item 5. Other Information Rule 10b5 - 1 Trading Plans During the nine months ended September 30, 2025 , none of our directors or officers entered into, modified or terminated a “Rule 10b5 - 1 trading arrangement” or “non-Rule 10b5 - 1 trading arrangement,” that were intended to satisfy the affirmati… | |
| 2025-08-14 10-Q | Rule10b51Arr Adopted | 2025-01-01..2025-06-30 | No | |
| 2025-08-14 10-Q | Non Rule10b51Arr Adopted | 2025-01-01..2025-06-30 | No | |
| 2025-08-14 10-Q | Rule10b51Arr Terminated | 2025-01-01..2025-06-30 | No | |
| 2025-08-14 10-Q | Non Rule10b51Arr Terminated | 2025-01-01..2025-06-30 | No | |
| 2025-05-15 10-Q | Rule10b51Arr Adopted | 2025-01-01..2025-03-31 | No | |
| 2025-05-15 10-Q | Non Rule10b51Arr Adopted | 2025-01-01..2025-03-31 | No | |
| 2025-05-15 10-Q | Rule10b51Arr Terminated | 2025-01-01..2025-03-31 | No | |
| 2025-05-15 10-Q | Non Rule10b51Arr Terminated | 2025-01-01..2025-03-31 | No | |
| 2025-03-21 10-K | Rule10b51Arr Adopted | 2024-10-01..2024-12-31 | No | |
| 2025-03-21 10-K | Non Rule10b51Arr Adopted | 2024-10-01..2024-12-31 | No | |
| 2025-03-21 10-K | Rule10b51Arr Terminated | 2024-10-01..2024-12-31 | No | |
| 2025-03-21 10-K | Non Rule10b51Arr Terminated | 2024-10-01..2024-12-31 | No | |
| 2025-03-21 10-K | Award Timing MNPI Disclosure | 2024-01-01..2024-12-31 | We do not have a written policy in place regarding the timing of the grant and issuance of stock options in relation to the release of material non-public information. Historically, we have typically granted stock option awards shortly after the completion of our annual meeting of shareholders, and … | |
| 2025-03-21 10-K | Award Timing Method | 2024-01-01..2024-12-31 | We do not have a written policy in place regarding the timing of the grant and issuance of stock options in relation to the release of material non-public information. Historically, we have typically granted stock option awards shortly after the completion of our annual meeting of shareholders, and … | |
| 2025-03-21 10-K | Award Timing Predetermined | 2024-01-01..2024-12-31 | Yes | |
| 2025-03-21 10-K | Award Timing How MNPI Considered | 2024-01-01..2024-12-31 | We have not intentionally timed the grant of stock options in anticipation of the release of material nonpublic information | |
| 2025-03-21 10-K | Award Timing MNPI Considered | 2024-01-01..2024-12-31 | Yes | |
| 2025-03-21 10-K | MNPI Disclosure Timed For Compensation Val | 2024-01-01..2024-12-31 | No | |
| 2024-11-14 10-Q | Rule10b51Arr Adopted | 2024-07-01..2024-09-30 | No | |
| 2024-11-14 10-Q | Non Rule10b51Arr Adopted | 2024-07-01..2024-09-30 | No | |
| 2024-11-14 10-Q | Rule10b51Arr Terminated | 2024-07-01..2024-09-30 | No | |
| 2024-11-14 10-Q | Non Rule10b51Arr Terminated | 2024-07-01..2024-09-30 | No | |
| 2024-08-14 10-Q | Rule10b51Arr Adopted | 2024-01-01..2024-03-31 | No | |
| 2024-08-14 10-Q | Non Rule10b51Arr Adopted | 2024-01-01..2024-03-31 | No | |
| 2024-08-14 10-Q | Rule10b51Arr Terminated | 2024-01-01..2024-03-31 | No | |
| 2024-08-14 10-Q | Non Rule10b51Arr Terminated | 2024-01-01..2024-03-31 | No | |
| 2024-05-15 10-Q | Rule10b51Arr Adopted | 2024-01-01..2024-03-31 | No | |
| 2024-05-15 10-Q | Non Rule10b51Arr Adopted | 2024-01-01..2024-03-31 | No | |
| 2024-05-15 10-Q | Rule10b51Arr Terminated | 2024-01-01..2024-03-31 | No | |
| 2024-05-15 10-Q | Non Rule10b51Arr Terminated | 2024-01-01..2024-03-31 | No |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |